VIRONIX HEALTH PRESENTS INNOVATIVE RESEARCH METHODS FOR CHRONIC KIDNEY DISEASE PROGRESSION

Vironix Health is proud that we presented earlier this week at the Machine Learning for Health (ML4H) Symposium in Vancouver, Canada. The ML4H Symposium brings together machine learning researchers, clinicians, and healthcare data scientists to hear, discuss, and learn about the latest innovations and groundbreaking research in healthcare. Our published research, “Integrated Machine Learning and Survival Analysis Modeling for Enhanced Chronic Kidney Disease Risk Stratification” is available here: https://arxiv.org/pdf/2411.10754

Chronic kidney disease (#CKD) is a significant public health challenge that can progress to end-stage renal disease (#ESRD) if not detected and managed early. The early identification of disease progression allows interventions to reduce morbidity, mortality, and financial burden. Early detection and management of CKD can prevent the need for invasive treatments including dialysis and kidney transplantation, significantly improving the quality of life for ESRD patients.

Our collaborating researchers, Sumanth Swaminathan, Botros Toro, Ammar Naseer, and Zachary Dana, applied a novel approach to model CKD degeneration using a combination of #machinelearning techniques and classical statistical models. Our research contributions were threefold:

Identification of novel predictors for CKD degeneration beyond those established in the kidney failure risk equation
Improved predictive performance in CKD survival analysis modeling, evidenced by enhanced concordance index and Brier scores
Comparative analysis in model-based feature selection, extending previous research methodology through the integration of deep learning architectures

Researcher Zachary Dana said, “We were honored to be accepted into the prestigious ML4H Symposium. Our team applied an innovative method to identify new predictors of CKD progression, and we are excited to contribute to the global conversation on machine learning in healthcare alongside forward-thinking researchers.”

Co-author Ammar Naseer pointed out, “By combining machine learning with survival analysis, this study uncovers complex nuanced patterns in CKD progression — a disease often characterized by silent progression. This approach improves the predictive accuracy of CKD models and lays a foundation for timely, personalized interventions, with the potential to positively influence disease trajectories and patient outcomes.”

🌟 Dr. Sumanth Swaminathan, Vironix CEO and co-founder, said enthusiastically, “Vironix continues our involvement in ground-breaking scientific research using the latest technologies. Preventing disease progression is one of our most important ways to improve healthcare for patients with chronic illnesses. We apply research findings to our AI-powered algorithms we use every day for virtual care management.”

To learn how you can benefit from Vironix Health Inc.’s scientific research expertise in AI-enhanced chronic disease management, visit: https://www.vironix.ai/.